![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Salarius Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing potential new cancer medicines for patients in need of new treatment options. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader. Salarius Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing potential new cancer medicines for patients in need of new treatment options. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
Patients were treated in the dose-escalation portion of the Phase 1/2 study evaluating seclidemstat in combination with azacitidine Investigators reported a 43% overall response rate among 14...
HOUSTON, June 12, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop...
Patient Enrollment Resumed in the Investigator-initiated Phase 1/2 Clinical Trial of Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Company Implemented Significant...
Period β | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.49 | -16.3333333333 | 3 | 3 | 2.3 | 74186 | 2.47372585 | CS |
4 | 2.0468 | 441.882556131 | 0.4632 | 3.88 | 0.3868 | 72803 | 1.59303647 | CS |
12 | 2.045 | 439.784946237 | 0.465 | 3.88 | 0.3868 | 43659 | 1.09417604 | CS |
26 | 1.922 | 326.870748299 | 0.588 | 3.88 | 0.3868 | 77151 | 0.6906 | CS |
52 | 1.14 | 83.2116788321 | 1.37 | 3.88 | 0.3868 | 64732 | 0.74409713 | CS |
156 | -26.49 | -91.3448275862 | 29 | 30 | 0.3868 | 387070 | 12.68131563 | CS |
260 | -286.24 | -99.1307359307 | 288.75 | 370.385 | 0.3868 | 555328 | 28.55748589 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions